Helix BioPharma Corp. HBPCF
0.77 USD 0.00 (+0.00%)
At closeNov 4, 2026, 4:00 PM EST
0.77 Day range 1.71
0.77 52-week range 1.73
- YTD
- -55.49%
- 1 year
- -55.49%
- Market cap
- 58.81M
- EPS (ttm)
- -0.031368
- P/E ratio
- -24.55
- YTD return
- -55.49%
- 1-year return
- -55.49%
- Volume
- 100
- Avg volume
- 3
- Open
- 0.77
- Previous close
- 0.77
- Day's range
- 0.77 – 1.71
- 52-week range
- 0.77 – 1.73
YTD -0.9600 (-55.49%)
Financials — quick view
HBPCF Revenue — quarterly 1.00M
HBPCF Net income — quarterly -2.87M
HBPCF EPS — quarterly -0.04
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Dec 16, 2024 | Oct 1, 2024 | 0.00 | -0.02 | — | — |
| Oct 24, 2024 | Jul 1, 2024 | 0.00 | -0.08 | — | — |
| Jun 14, 2024 | Apr 1, 2024 | 0.00 | 0.00 | — | — |
| May 13, 2024 | Jan 1, 2024 | 0.00 | 0.00 | — | — |
| Dec 14, 2023 | Oct 1, 2023 | 0.00 | -0.05 | — | — |
| Oct 27, 2023 | Jul 1, 2023 | 0.00 | -0.05 | — | — |
News
Helix BioPharma Corp. Appoints Markus Loeffler, MD, MBA, as Chief Medical Officer to Support Next Phase of Clinical Development 
Helix Biopharma Corp. Announces Board Composition Changes 
Helix BioPharma Corp. Strengthens Executive Leadership to Support U.S. Listing Strategy and Next Phase of Clinical Development 
Helix Biopharma Corp. Announces Financial Results and Filing of Interim Financial Statements as of and for the Three- and Nine-Month Periods Ended April 30, 2026 
Helix BioPharma Corp. Announces Closing of Private Placement of Convertible Debentures 
Helix BioPharma Corp. Announces Grant and Cancellation of Stock Options 
Helix Biopharma Corp. Announces Strategic Board and Governance Appointments to Support Financing and Nasdaq Uplisting Strategy 
Helix BioPharma Corp. Announces Financial Results and Filing of Interim Financial Statements as of and for the Three- and Six-Month Periods Ended January 31, 2026 
Helix BioPharma Corp. Announces Presentation at 16th Annual World ADC London 
Helix Biopharma Corp. Extends LEUMUNA Option with metaShape Pharma for Adipose Tissue-Related and Metabolic Diseases
Your note
Sign in to keep a note on HBPCF — it syncs with the Stock Master app.